Reuters logo
1 个月内
BRIEF-Cara Therapeutics reports continuation of phase 3 trial of I.V. CR845 in postoperative pain
2017年6月21日 / 上午11点12分 / 1 个月内

BRIEF-Cara Therapeutics reports continuation of phase 3 trial of I.V. CR845 in postoperative pain

1 分钟阅读

June 21 (Reuters) - Cara Therapeutics Inc:

* Cara Therapeutics reports continuation of phase 3 trial of i.v. Cr845 in postoperative pain following interim assessment

* Cara Therapeutics - ‍based on guidance of idmc, trial will continue to test 2 doses of cr845 versus placebo in up to 450 patients undergoing abdominal surgery​

* Cara Therapeutics Inc - trial will continue to test two doses of cr845 and aims to enroll up to 450 patients

* Cara Therapeutics Inc - both doses of cr845 well tolerated

* Cara Therapeutics Inc - trial completion expected in q4 of 2017 for cr845 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below